NYSE
65.04USD
-0.14 (-0.21%)
We have scored 35 news catalysts on Alcon Inc. (ALC) over the past 12 months. The biggest single-day move next to one of them came Jul 21, 2026, when ALC closed −3.8%: “Dow jumps 230 points as chip stocks rebound ahead of Big Tech earnings”. Coverage across the window leans positive (average ticker sentiment +0.17). Most of the impact sits in sector healthcare and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
31.7B
P/E
—
EPS
—
Beta
0.70
52W range
61.835-87.64
Day range
64.54–65.60
Open
64.75
Prev close
65.18
Volume
3.4M
Avg volume
2M
Dividend
0.36
IPO
2019-04-09
Analysts publish price targets on ALC, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
8 analyst price targets from $35 to $85
as of 2026-09-02
The market is 10% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Alcon Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Alcon Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ALC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
The price sits at the 25th percentile of published models, leaning bearish against the analyst set by paying for a modest growth path but refusing both the bull case for sustained mid-single-digit expansion and the bear case for margin collapse.
What the disagreement turns on
Whether Alcon can accelerate organic surgical and vision care volume growth to meet the 8.2% revenue CAGR the price requires, which can be tested via unit_volumes data but not via the currently wired pricing or consumer attention tools.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $71.75 on 2026-09-02 — the quote has since moved -9%, so read this as a record of what was priced in then, not now.
